Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM).
Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing a long-term continuous glucose monitor (CGM) for people with type 1 diabetes.
With an aim to commercialize a long-term sensor, Glucotrack hopes its offering will have no requirement for an additional wearable component. The company also hopes for a once-only calibration for the platform. It believes these can serve as key differentiators in the CGM market.
Get the full story at our sister site, Drug Delivery Business News.